Protocol Ledger

NCT07005336 · Phase II · ACTIVE NOT RECRUITING

A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung

Interventional Phase II clinical trial protocol NCT07005336 sponsored by TJ Biopharma Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-01-09 Enrollment: 150 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07005336
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)150 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07005336
Protocol FieldVerified Registry Value
NCT IdentifierNCT07005336
Consolidated Lead SponsorTJ Biopharma Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment150 participants (ESTIMATED)
Registered Start Date2025-01-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07005336
Hospital Research SiteLocationSite Profile
Sichuan Cancer HospitalChengdu, ChinaOpen Hospital Dossier ->
Anhui Provincial Cancer HospitalHefei, ChinaOpen Hospital Dossier ->
The First Affiliated Hospital of Anhui Medical UniversityHefei, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI